fig2
![MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression](https://image.oaes.cc/110f735f-64b9-49ee-9793-5d4b2035bc3f/3433.fig.2.jpg)
Figure 2. MEKi treatment increases immue-associated protein expression and antigen presentation in murine mammary cancer cell lines. A: MMTV-Neu, 4T1, EMT6, and E0771 murine mammary cells were treated with or without trametinib (50 nM; MEKi) for 72 h prior to flow cytometry analysis for MHC-I and PD-L1 expression; (n = 3); B: E0771 and E0771-Ova cells were treated with or without trametinib (50 nM; MEKi) for 72 h prior to flow cytometry analysis for MHC-I (H2Kb), MHC-I bound to SIINFEKL (H2KB-SIINFEKL) and PD-L1 expression. (n = 3). MEKi: MEK inhibition; DMSO: dimethylsulfoxide